Istinye University, in collaboration with Liv Hospital and the Perelman School of Medicine at the University of Pennsylvania, one of the world’s leading higher education institutions, aims to develop new approaches to treating resistant cancers. Additionally, the cells used in these treatments will be produced in Turkey.
Through the protocol established between Istinye University, Liv Hospital, and the Perelman School of Medicine, the partnership seeks to implement new approaches to cell and proton therapies for resistant cancer through joint clinical activities. A wide range of projects will progress simultaneously, from clinical applications to second opinion systems, international training programs, and cell production laboratories. The scientific conferences organized through this protocol will allow Perelman Medical School experts to share their knowledge and experience with Turkish healthcare professionals. In addition, online and face-to-face training programs will be launched for doctors at Istinye University and Liv Hospital.
Turkish Doctors Will Experience Global Applications Up Close
Especially for complex and advanced cases requiring treatment, the insights and evaluations of experts from the Perelman School of Medicine at the University of Pennsylvania will be made available to doctors at Istinye University and Liv Hospital. Doctors will have the opportunity to interact with their pioneering international colleagues and benefit from their perspectives.
“Scientific Collaborations Are the Driving Force of Transformation in Healthcare”
The collaboration will also provide a solid foundation for joint biomedical research. Projects carried out in compliance with international scientific and ethical standards aim to contribute to knowledge production, innovation, human health, and the future of treatments.
Prof. Dr. Erkan İbiş, the Rector of Istinye University, evaluated the partnership: “Scientific collaborations are the strongest driving force of transformation and progress in healthcare. This partnership with Liv Hospital and the Perelman School of Medicine, one of the most prestigious medical faculties in the world, marks a critical step towards bringing the future of cancer treatments to our country. As Istinye University, we continue to work with a vision to integrate research, education, and clinical applications globally, contributing to the best training of healthcare professionals and bringing hope to our patients.”
“Cells Used in Cancer Treatment Will Be Produced Here in Turkey”
Prof. Dr. Erdal Karaöz, Director of the Regenerative Medicine and Stem Cell Center at Liv Hospital, emphasized the pioneering nature of this collaboration in Turkey with the Perelman School of Medicine, a global leader in cancer research and treatment. Prof. Dr. Karaöz said, “Liv Hospital will be the first in Turkey to apply cellular treatments in this context. Through the international-standard laboratories we are establishing with Istinye University, we are preparing to produce the cells used in this treatment within our own facilities.”
“We Are Moving Forward with a Vision That Also Considers the Future”
Meri İstiroti, Liv Hospital Group Coordinator and Member of the Executive Board at Istinye University, stated that this collaboration would not only strengthen the partner institutions but also enhance Turkey’s position in global healthcare. She believes this partnership will create inspiring opportunities for patients, students, and young researchers:
“We view scientific partnerships not just as an exchange of knowledge, but as a powerful interaction that directly touches human life and transforms the future. As Liv Hospital and Istinye University, we are moving forward with a vision that considers not only today but also the future of healthcare. This collaboration with a longstanding and innovative institution like the Perelman School of Medicine at the University of Pennsylvania is a significant step in strengthening Turkey’s position in global healthcare. With clinical programs that will facilitate access to advanced treatment methods and joint research projects that will support scientific production, we aim to add value to every layer of healthcare services. I believe this agreement will create inspiring opportunities not only for our institutions but also for patients, students, and young researchers.”
